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ABSTRACT 
In the present study we investigated the effects of the somatostatin 
(SS) analogs octreotide, RC-160, and BIM-23014 on GH release by 
cultured cells of human GH-secreting pituitary tumors, in normal rat 
anterior pituitary cells, and on gastrin release by cultured cells from a 
human gastrinoma. 
In all GH-secreting adenomas and in rat anterior pituitary cells, 
RC-160 was the most potent compound. RC-160 significantly inhibited 
GH-, PRL, and/or a-subunit release by human GH-secreting pituitary 
adenoma cells in concentrations as low as 10-‘2-10-14 M, whereas at the 
same concentrations, octreotide and BIM-23014 did not inhibit or were 
significantly less effective in inhibiting GH release (P < 0.01, RC-160 
us. octreotide and BIM-23014). In rat-anterior pituitary cell cultures, 
the IC,, values for inhibition of GH release were. in rank order of 
potency, 0.1, 5.3, 47, 48, and 99 PM for RC-160, SS-14, BIM-23014, 
octreotide, and SS-28, respectively. Maximal inhibitory effects by the 
three analogs were the same in the human GH adenoma cell cultures 
and the rat anterior pituitary cell cultures (-60%). On the basis of 
these data, RC-160 appears to be about 500 times more potent than 
octreotide and BIM-23014 in inhibiting GH release bv rat anterior 
pituitary cells in uitro. Forskolin (100 $4) as well as pretreatment of 
the ce1G with pertussis toxin significantly diminished the inhibitory 
effects of the three SS analogs and those of SS-14 and SS-28 to the 
same extent. The latter data siggest that octreotide, RC-160, and BIM- 
23014 act mainly via a pertussis toxin-sensitive G-protein and an 
adenylyl cyclase-dependent mechanism. In the human gastrinoma cul- 
ture, RC-160 inhibited gastrin release significantly more than octreo- 
tide at lo-“- and 10-14-M concentrations-(P < O.Oi). 
In conclusion. the SS analogs octreotide. RC-160. and BIM-23014 
may have significant different potencies bf inhibition of hormone 
release in u&o, with RC-160 being the most potent SS analog and 
octreotide and BIM-23014 having similar potencies. Depending on the 
pharmacokinetic properties of these three octapeptide SS analogs, these 
observations may have consequences for the medical therapy of patients 
with SS receptor-positive endocrine tumors. (Endocrinology 134: 301- 
306,1994) 
S OMATOSTATIN-14 (SS-14) is a tetradecapeptide that has inhibitory effects in a variety of endocrine tissues 
(1). The effects of SS (analogs) are mediated via high affinity 
membrane receptors belonging to the family of G-protein- 
coupled receptors. For clinical use, primarily in the treatment 
of GH hypersecretion in patients with GH-secreting pituitary 
adenomas, several analogs of SS have been developed, which 
have a considerably longer biological half-life than SS-14 
and do not cause a rebound GH hypersecretion as has been 
shown for SS-14 (2). Of these analogs, octreotide, BIM- 
23014, and RC-160, only octreotide has obtained clinical 
importance so far (2). Bauer et al. (3) originally developed 
the highly potent octapeptide analog octreotide. Thereafter, 
several analogs related to octreotide were synthesized and 
tested for their biological activity by Cai et al. (4, 5). The 
latter investigators suggested that RC-160, one of their ana- 
logs, might be more specific for GH inhibition and had lower 
activity for inhibition of insulin and glucagon release in viva. 
In addition, Liebow and co-workers (6) demonstrated an 
effect of RC-160, but not octreotide, on cell growth and 
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tyrosine phosphatase activity in the Mia-PaCa-2 human 
pancreatic tumor cell line. On the basis of recent data by 
other investigators, this discrepancy between the effects of 
RC-160 and octreotide can be challenged, however (7, 8). 
In vitro studies have shown differential binding of SS 
analogs in normal rat brain and adenohypophysis (9). In 
certain human tumors (breast cancer, ovarian cancer, and 
pancreatic cancer), differences in binding characteristics have 
been reported between octreotide and RC-160 (10). 
The above data suggest that in normal tissues and in 
certain tumors, there may be differences in receptor binding 
characteristics and biological effects among the different SS 
analogs. However, there are as yet no in vitro studies that 
compare the effects of all three of the above-mentioned SS 
analogs in an established culture system and in primary 
cultures of SS receptor (SS-R)-positive endocrine tumors. In 
the present study, therefore, we compared the inhibitory 
effects of octreotide, BIM-23014, and RC-160 on GH release 
by cultured human GH-secreting pituitary adenoma cells 
and rat anterior pituitary cells and those of octreotide and 
RC-160 on gastrin release by a cultured human gastrinoma. 
In addition, we performed experiments dealing with the 
mechanism of action of inhibition of GH release by these SS 
analogs in the human GH adenoma and rat anterior pituitary 
cell cultures. 
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Materials and Methods 
Cell culture 
Tumor tissue from eight untreated acromegalic patients (patients l- 
8) was obtained by transsphenoidal operation. Single cell suspensions 
of the adenoma tissue were prepared by enzymatic dissociation with 
dispase, as described in detail previously (11). 
Tumor tissue from a patient with a gastrinoma was dissociated with 
collagenase (type I, Sigma Chemical Co., St. Louis, MO), as described 
previously (12). 
Dispersed rat anterior pituitary cells were prepared by enzymatic 
dissociation of anterior pituitaries from female Wistar rats, weighing 
180-200 g, as previously described in detail (13). Animals were kept, 
treated, and cared for in accordance with the guidelines approved by 
the European Community on November 24, 1986. 
The cells were plated at a density of lo5 cells/well in 1 ml culture 
medium in multiwell plates (48 wells; Costar, Cambridge, MA). The 
human GH-secreting tumor cells and human gastrinoma cells were 
allowed to attach for 4 days at 37 C in a CO2 incubator. Thereafter, the 
medium was changed, and 24- or 96-h incubations without or with test 
substances were carried out in quadruplicate. The rat anterior pituitary 
cells were allowed to attach for 4 days, after which the medium was 
changed. After another medium change on day 7 of culture, 4-h incu- 
bations without or with test substances were performed in quadruplicate. 
In the experiment with pertussis toxin (PT), the cells were preincubated 
for 2 h with PT before the 4-h incubation. At the end of the incubation, 
the medium was removed and centrifuged for 5 min at 600 x g, and the 
supematant was stored at -20 C until analysis. Forskolin and PT were 
used in concentrations of 100 PM and 50 fig/liter, respectively. 
The culture medium in all experiments was Minimum Essential 
Medium with Earle’s salts (MEM) supplemented with nonessential 
amino acids, sodium p ruvate (1 mmol/liter), 10% fetal calf serum 
(FCS), penicillin (1 X 10 Y U/liter), fungizone (0.5 mg/liter), L-glutamine 
(2 mmol/liter), and sodium bicarbonate (2.2 g/liter). The medium was 
adjusted to pH 7.4 with 1 mol/liter NaOH. 
Test substances 
PT and 58-14 were obtained from Sigma. Forskolin was obtained 
from Calbiochem Corp. (La Jolla, CA). BIM-23014 (SS tumor-inhibiting 
analog) and SS-28 were obtained from Bissendorf Biochemicals (Han- 
nover, Germany). RC-160 was obtained from Peninsula (Belmont, CA). 
Octreotide was obtained from Sandoz (Basel, Switzerland). 
The structures of octreotide, BIM-23014, and RC-160 are shown in 
Fig. 1. 
Hormone determinations 
Human GH and PRL concentrations in the culture medium were 
determined by immunoradiometric assays, as described previously (11). 
Glycoprotein a-subunit concentrations in the medium were determined 
by a double antibody RIA, as described previously (11). Rat GH and rat 
PRL concentrations were determined by double antibody RIAs, using 
materials supplied by the NIDDK, as described in detail previously (13, 
14). 
Gastrin concentrations were determined by a double antibody RIA 
from Diagnostic Products Corp., as described previously (12). 
Octreotide: 
I 1 
D-Pha-Cys-Phe-D-Trp-Lys-Thr-Cys-Th 
I I 
BIM-23014: D-bNal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr. 
tt t 
I I 
RC-160: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp 
t t t 
FIG. 1. Structures of the SS analogs octreotide, BIM-23014, and RC- 
160. Arrows indicate differences from octreotide. 
Data analysis 
The statistical significance of the differences between mean values 
was determined using two-way analysis of variance. When significant 
overall effects were obtained by analysis of variance, multiple compar- 
isons were made using the Newman-Keuls test (15). Differences were 
considered significant when P < 0.05. Each experiment with rat anterior 
pituitary cells is representative of at least two independent experiments. 
Results 
Effects of SS analogs on GH-, PRL-, and a-subunit release by 
cultured human GH-secreting pituitary adenoma cells 
Table 1 shows the effects of octreotide, BIM-23014, and 
RC-160 on GH release by five cultures of human GH- 
secreting pituitary adenoma cells. In all cultures, GH release 
was significantly inhibited by the three analogs in a dose- 
dependent fashion. Although the maximal inhibitory effects 
of the analogs were comparable in all cultures, there were 
considerable differences in the concentration range over 
which the analogs inhibited GH release. RC-160 significantly 
inhibited GH release in concentrations up to lo-‘* M in four 
cultures (patients 1-4; P < 0.01 VS. control) and in a concen- 
tration up to lo-l4 M in one culture (patient 5), whereas at 
these concentrations, octreotide and BIM-23014 did not in- 
hibit or were significantly less effective (P < 0.01 VS. effect 
of RC-160 in cultures of patients 1, 2, 3, and 5; P < 0.05 vs. 
effect of RC-160 in culture of patient 4) in inhibiting GH 
release in five cultures (patients l-5) and four cultures (pa- 
tients 2-5), respectively. Although in most cultures, a 24-h 
incubation with the SS analogs was performed (except in the 
culture of patient 3, which represents a 96-h incubation), we 
found a comparable difference in the potencies of GH inhi- 
bition between RC-160, octreotide, and BIM-23014 in cul- 
tures that were incubated for 4 or 96 h (data not shown), 
suggesting that the differences in the potencies between the 
analogs are not due to degradation of the drugs. In four 
cultures (patients 1, 3, 5, and 6) that secreted PRL and/or (Y- 
subunit as well as GH, the effects of octreotide and RC-160 
on all three hormones were comparable. Again, RC-160 was 
significantly more potent than octreotide in inhibiting hor- 
mone release (GH, PRL, and a-subunit). As an example, Fig. 
2 shows that in the culture from patient 6 (not shown in 
Table l), RC-160 was significantly more effective (in concen- 
trations of lo-*’ and lo-l4 M) than octreotide (P < 0.01 VS. 
effect of octreotide) in inhibiting GH, PRL, and a-subunit 
release. Two other cultures (patients 7 and 8) that secreted 
GH and PRL simultaneously showed a low sensitivity of 
PRL release to the inhibitory effects of the somatostatin 
analogs, whereas GH release was significantly inhibited at 
the same time (Table 2). This demonstrates the specificity of 
the effects of the SS analogs. To study the involvement of a 
G-protein in the inhibitory effects of octreotide, BIM-23014, 
and RC- 160, the cells from two cultures were pretreated with 
PT. In both cultures (patients 4 and 5), PT significantly 
reduced the inhibitory effect of the three SS analogs on GH 
release, although this was most evident in the culture from 
patient 5. This is shown in Table 3. 
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TABLE 1. The effects of octreotide (OCTR), RC-160, and BIM-23014 on GH release by cultured human GH-secreting pituitary tumor cells 
Dw COIlC. Patient 1 Patient 2 Patient 3 Patient 4 
(log Ml (24 h) (24 h) (96 U (24 h) 
OCTR 0 1663 f 47 (100) 8083 f 321 (100) 1468 + 35 (100) 48 f l(lO0) 
-6 783 f 49 (47)” 2899 f 146 (36)” 454 + 5 (31)” 
-8 585 k 25 (35)” 2664 + 102 (33)” 403 + 10 (27)” 35 + 2 (73)” 
-10 707 k 27 (43)” 3047 f. 80 (38)” 442 2 8 (30)” 40 + 2 (83)‘~~ 
-12 1303 + 43 (78)“” 7627 + 316 (94)” 848 + 44 (58)“*’ 48 + 2 (lOO)d 
-14 - - - 
RC-160 -6 597 + 20 (36)” 2267 + 205 (28)” 527 + 12 (36)” - 
-8 553 + 25 (33)” 2133 f 192 (26)” 437 2 26 (30)” 33 z!z 2 (69)” 
-10 593 + 28 (36)” 2000 k 29 (25)” 413 + 15 (28)” 37 + 1 (77)” 
-12 810 + 62 (49)qd 2967 + 148 (37)“,’ 470 5 25 (32)” 41 -t 2 (85)’ 
-14 - - 
BIM-23014 -6 2200 + 29 (27)” 427 + 12 (29)’ 
-8 - 2000 + 29 (25)” 405 + 25 (28)” 35 + 2 (73)” 
-10 - 2633 + 192 (33)” 465 + 5 (32)” 47 + 1 (98)’ 
-12 - 4533 + 219 (56)“~’ 765 + 15 (52)“rd 46 + 2 (96) 
-14 - - - 
n = 4 wells/treatment moue. -. Not tested. Numbers in narentheses refer to the percentage of control release. 
a P < 0.01 IL. control. - - 
‘P C 0.05 vs. control. 
’ P < 0.01 vs. previous lower concentration of SS analog. 
d P < 0.05 vs. previous lower concentration of SS analog. 
Patient 5 
(24 h) 
1149 + 29 (100) 
400 k&35)” 
415 + 5 (36)” 
773 + 29 (67)“l’ 
1024 f 38 (89) **’ 
- 
377 f 19 (33)” 
401 + 15 (35)” 
523 + 40 (46)“~’ 
530 + 7 (46)” 
- 
520 f 16 (45)” 
642 + 21 (56)“~’ 
825 + 26 (72)“” 
1011 AZ 34 (88)bs’ 
Effects of 5’S analogs on gastrin release by human 
gastrinoma cells 
Figure 3 shows the effects of octreotide and RC-160 on 
gastrin release by cultured cells from a human gastrinoma. 
Both analogs significantly inhibited gastrin release in a dose- 
dependent manner in concentrations as low as lo-i4 M (oc- 
treotide: lo-l4 US. 10-l’ M, P < 0.05; 10-l’ DS. 10-l’ M, P < 
0.01; RC-160: lo-l4 us. 10-l’ M, P < 0.05). However, at 10-l’ 
and lo-l4 M, RC-160 inhibited gastrin release significantly 
more than octreotide (P < 0.01 us. effect of octreotide). Again, 
the maximal inhibitory effects of octreotide and RC-160 were 
similar. Insufficient cells were isolated from this tumor to 
study the effect of BIM-23014. 
Effects of SS analogs, SS-14, and SS-28 on GH release by 
cultured rat anterior pituitary cells 
In Fig. 4, the effects of octreotide, BIM-23014, RC-160, 
SS-14, and SS-28 on GH release by cultured rat anterior 
pituitary cells are shown. All SS (analogs) inhibited GH 
release maximally and to the same extent (by -60%) at lOmE 
M. However, the dose-response curve of RC-160 was signif- 
icantly different from those of SS-14, BIM-23014, octreotide, 
and SS-28. Although RC-160 significantly inhibited GH 
release up to lo-i4 M, no other somatostatin (analogs) signif- 
icantly inhibited GH release at lo-” or lo-l4 M. ICso values 
for inhibition of GH release were, in rank order of potency, 
0.1, 5.3, 47, 48, and 99 PM for RC-160, SS-14, BIM-23014, 
octreotide, and SS-28, respectively. On the basis of these 
data, RC-160 appears to be about 500 times more potent 
than octreotide and BIM-23014 in inhibiting GH release by 
rat anterior pituitary cells in vitro. In 24- and 96-h incuba- 
tions, this significant difference in the potency of inhibition 
of GH release among RC-160, octreotide, and BIM-23014 
was still present (data not shown), but at the same time the 
IC,, value of inhibition of GH release by SS-14 was signifi- 
cantly lower (500 and 8700 PM, respectively), pointing to 
degradation of SS-14, but not of the SS analogs. 
We also investigated the effect of a 2-h preincubation with 
50 pg/liter PT. Table 4 shows that pretreatment of the cells 
with PT significantly reduced the inhibitory effects of the 
three SS analogs, SS-14, and SS-28 on GH release. In addi- 
tion, simultaneous exposure of the cells to a maximally active 
concentration of forskolin (100 PM) resulted in significantly 
less inhibition of GH release by all SS analogs tested (Table 
4; P < 0.01 ZIS. percent effect on control untreated cells). 
Discussion 
The present study shows for the first time that the SS 
analogs octreotide, BIM-23014, and RC-160 have different 
potencies of inhibition of GH release by primary cultures of 
human GH-secreting pituitary tumor cells and normal rat 
anterior pituitary cells, and of inhibition of gastrin release by 
a primary culture of a human gastrinoma in vitro. In all cases, 
RC-160 was clearly the most potent in its inhibitory action. 
Although the in vivo and in vitro effects of octreotide, BIM- 
23014, and RC-160 have been studied extensively, no studies 
have been performed so far comparing simultaneously the 
three SS analogs available for clinical use in primary cultures 
of human endocrine tumor cells and rat anterior pituitary 
cells. 
Bauer et al. (3) originally developed a series of highly 
potent octapeptide analogs of SS-14, of which octreotide was 
the most active. Thereafter, several other analogs, related to 
octreotide, were synthesized and tested for their biological 
activity by Cai and co-workers (4, 5). Cai et al. found that 
substitution of Phe and Thr by Tyr and Val, respectively, at 
positions 3 and 6 resulted in a much higher potency for 
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FIG. 2. Dose-response relationship of the effects of the SS analogs 
octreotide and RC-160 on hormone release by a cultured mixed GH-, 
PRL-, and cy-subunit-secreting human pituitary adenoma (patient 6). 
Cells (10’) were cultured for 4 days in MEM-10% FCS. On day 4 of 
culture, the medium was changed, and a 24-h incubation without or 
with octreotide (0) and RC-160 (0) was performed in quadruplicate. 
Values are the mean + SE. 
inhibition of GH secretion, but lower activity for inhibition 
of insulin and glucagon release in viva in rats. They also 
suggested that replacing Thr at position 8 by Trp may result 
in increased receptor affinity. This suggests that the Tyr3/ 
VaP-containing series of analogs might be more specific for 
GH inhibition, and there may be selectivities in the biological 
actions of SS octapeptide analogs. Both RC-160 and BIM- 
23014 are Tyr3/Va16-containing analogs, whereas RC-160 
also has Trp at position 8. On the basis of the results from 
our present study, we can confirm this high potency of 
inhibition of GH secretion by RC-160 in cultures of human 
GH-secreting pituitary adenomas and in one culture of a 
human gastrinoma. In GH-secreting pituitary adenomas, oc- 
treotide and BIM-23014 inhibited GH release to the same 
extent, whereas RC-160 was clearly the most active com- 
pound. In cultured rat anterior pituitary cells, RC-160 was 
about 500 times more potent than octreotide and BIM-23014. 
TABLE 2. Effects of SS analogs on GH and PRL release by 
cultured GH-secreting pituitary adenoma cells 
Patient 
no. Treatment 
GH PRL 
bdliW Wl~~4 
I Control 1583 f 75 165 + 3 
Octr (IO-’ M) 808 f 51 (51)O 177 + 6 (107) 
BIM (lo-’ M) 950 + 33 (60)” 190 f 6 (115) 
RC (lo-’ M) 938 + 17 (59)” 157 f 7 (95) 
8 Control 269 + 17 51 f 3 
Octr (10-l’ M) 138 + 4 (51)” 43 f 2 (&I)* 
RC (lo-” M) 138 f 6 (51)” 43 + 2 (84)b 
n = 4 wells/treatment. The incubation times were 24 and 96 h for 
cultures from patients 7 and 8, respectively. Octr, Octreotide; BIM, 
BIM-23014; RC, RC-160. Values are the mean I SE. Numbers in 
parentheses refer to the percentages of control values. 
D P < 0.01 us. control cells. 
* P C 0.05 us. control cells. 
TABLE 3. Effects of pretreatment with PT on the inhibitory 
effects of octreotide (O&r), RC-160 (RC), and BIM-23014 (BIM) on 
GH release by cultured human GH-secreting pituitary adenoma cells 
Patient 
no. 
Treatment 
GH release (rig/well) 
-PT +PT 
4 Control 48 f 1 59f 1” 
Octr (lo-’ M) 35 f 2 (73)b 49 + 1 (83)**’ 
BIM (lo-’ M) 35 f 2 (73)b 49 + 1 (83)*~’ 
RC (lo-’ M) 33 + 2 (69)* 48 f 1 (81)“’ 
5 Control 1149 + 29 1641 + 59” 
OCh (loe9 M) 398 + 7 (35)* 1452 + 47 (88)bvd 
BIM (lo-’ M) 608 + 6 (53)* 1521 + 59 (93)d,’ 
RC (1O-9 M) 388 + 12 (34)b 1284 + 22 (78)” 
n = 4 wells/treatment. Values are the mean + SE. The incubation 
time was 24 h for cultures from patients 4 and 5; before this 24-h 
incubation, the cells were preincubated for 2 h with 50 pg/liter PT. 
Numbers in parentheses refer to the percentages of control values. 
a P < 0.01 us. control without PT. 
* P C 0.01 us. control cells. 
‘P < 0.05 us. effect of SS analog on cells without PT. 
d P < 0.01 us. effect of SS analog on cells without PT. 
e P < 0.05 us. control cells. 
z 125 n 1 
0 -14 -12 -10 -8 -6 
log [peptide] (M) 
FIG. 3. Dose-response relationship of the effect of the SS analogs 
octreotide and RC-160 on gastrin release by cultured cells of a human 
gastrinoma. Cells (105) were cultured for 4 days in MEM-10% FCS. On 
day 4 of culture, the medium was changed, and a 24-h incubation 
without or with octreotide (m) and RC-160 (0) was performed in 
quadruplicate. Values are the mean f SE; basal gastrin release values 
are 13 & 1 and 15 f 0.5 rig/well, respectively. *, P < 0.01 us. control. 
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FIG. 4. Dose-response relationship of the effects of SS and SS analogs 
on GH release by cultured normal rat anterior pituitary cells. On day 
7 of culture, 4-h incubations were performed in quadruplicate. Values 
are expressed as a percentage of control GH release and represent the 
mean of two independent experiments. 0, RC-160; v, SS-14; A, BIM- 
23014; 0, octreotide; W, SS-28. 
TABLE 4. Effects of forskolin and PT on the inhibitory effects of 
SS and SS analogs on GH secretion by cultured rat anterior pituitary 
cells 
Treatment Control Forskolin 
(100 uM) 
PT 
(50 fig/liter) 
Control 
OCtr (lo-’ M) 
RC-160 (lo-’ M) 
BIM (10-s M) 
SS-14 (lo-’ M) 
SS-28 (lo-’ M) 
100 + 4 100 f  6 100 + 2 
41 + 3” 79 f  la,* 81 + la,* 
44 + 3” 18 + 2”fb 83 f  2”** 
43 + 2” 69 k 3”.* 92 + 2”tb 
41 rt 2” 68 + 3”.* 76 f  2”** 
31 f  3” 70 f  4”fb 74 * 4”** 
Rat anterior pituitary cells were cultured for 7 days. On day 7 of 
culture, 4-h incubations without or with test substances were performed 
in quadruplicate. Before this 4-h incubation, a 2-h preincubation with 
PT was performed. All effects are expressed as a percentage of the 
respective control value. Forskolin stimulated basal GH release to 345 
f  8% of control GH release. and PT sliehtlv stimulated GH release to 
I  ”  
117 + 5%. n = 4 wells/treatment group. Values are the mean + SE. 
Octr, Octreotide; BIM, BIM-23014. 
a P < 0.01 us. control. 
*P < 0.01 us. effect of SS (analog) in control cells. 
On the basis of many studies it has become evident that 
the SS-R shows both pharmacological and molecular heter- 
ogeneity, either within a particular SS-R-positive organ or 
between SS-R-positive organs (i.e. brain, pituitary, adrenal, 
and exocrine pancreas). With respect to the anterior pituitary 
gland, Pate1 et al. have shown, by cross-linking of SS-R 
proteins and using different SS-R ligands, the presence of 
three receptor proteins of 80, 58, and 27 kilodaltons in size 
(1, 16), whereas other investigators reported two subtypes of 
the receptor in the rat anterior pituitary gland which differ 
in size (82 and 94 kilodaltons) and sensitivity to estrogen 
regulation (17). Recently, five different SS-R genes have been 
cloned. Cultured cell lines that stably express these five 
recombinant SS-R genes have been established, and it is clear 
that these different genes are encoding for receptor proteins 
with approximately the same affinity for SS-14 and SS-28, 
but different affinities for the SS analogs octreotide and MK- 
678, demonstrating that there is a molecular basis for the 
observed pharmacological and molecular heterogeneities of 
SS-R (18). Finally, in a very small subgroup of human 
pituitary adenomas, Reubi et al. (19) found, using autoradi- 
ographic studies, SS-R with low affinity to octreotide and 
high affinity to SS-28, whereas the vast majority of the 
tumors showed high affinity to both ligands. At this moment 
we cannot exclude that the difference between the GH 
inhibitory effects of the SS analogs is caused by interaction 
with different SS-R subtypes. Comparative binding studies 
using the three SS analogs in cultured cell lines that stably 
express the somatostatin receptor subtypes might help to 
resolve this question. There are, however, several lines of 
evidence that argue against this hypothesis. First, we found 
comparable differences among the effects of octreotide, RC- 
160, and BIM-23014 in all GH-secreting pituitary adenomas, 
whereas SS-R with a low affinity for octreotide are found in 
only a small subgroup of the adenomas. Secondly, the max- 
imal inhibitory effects of octreotide, RC-160, and BIM-23014 
were the same in three culture systems we used in our study. 
Thirdly, a maximal concentration of forskolin as well as 
pretreatment of the cells with PT significantly reduced the 
inhibitory effects of the three SS analogs, SS-14, and SS-28 
to the same extent. In our experiments we performed a 2-h 
pretreatment with PT. A longer preincubation with PT might 
have completely blocked the inhibitory effect of the SS 
analogs. The latter data suggest that octreotide, RC-160, and 
BIM-23014 all act mainly via a PT-sensitive G-protein and 
adenylyl cyclase-dependent mechanism. Therefore, we sug- 
gest that the major differences among octreotide, BIM-23014, 
and RC-160 in their hormone release inhibitory effects are 
caused by differences in affinity for the same receptor. 
Although it is clear from our study that in all GH-secreting 
pituitary adenomas and in the gastrinoma studied, RC-160 
is clearly more potent in its inhibitory action on hormone 
release, the clinical significance of this finding has yet to be 
established. In previous studies comparing receptor binding 
characteristics with bioactivity in vim and in vitro, several 
investigators have shown that with certain SS analogs there 
may be a dissociation between binding characteristics and 
bioactivity (9, 20, 21). The dissociation constant of the SS-R 
is approximately 1 nM (22, 23). In normal men, SC adminis- 
tration of 100 pg octreotide was reported to result after 30- 
60 min in circulating octreotide levels of between 1.6-2.5 nM 
(24). In this nanomolar concentration range, however, we 
did not observe differences in the GH and gastrin release 
inhibitory effects among the three SS analogs studied. Only 
at significantly lower concentrations (picomolar range) did 
the differences between the analogs became evident. If this 
difference in the potency of inhibition of hormone release 
among RC-160, octreotide, and BIM-23014 is related to a 
difference among these SS analogs in affinity for the SS-R, 
it may have implications in the treatment of those tumors 
that have low affinity for octreotide but high affinity for SS- 
14 and SS-28, as has been reported in a subgroup of insuli- 
nomas, medullary thyroid carcinomas, carcinoids, and a 
small subgroup of GH-secreting pituitary adenomas (25). 
Moreover, Srkalovic et al. (10) previously showed that RC- 
160 had a significant higher affinity for SS-14-binding sites, 
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Srkalovic G, Cai R-Z, Schally AV 1990 Evaluation of receptors for 
somatostatin in various tumors using different analogs. J Clin En- 
docrinol Metab 70:661-669 
Hofland LJ, van Koetsveld PM, Verleun TM, Lamberts SWJ 1989 
Glycoprotein alpha-subunit and prolactin release by cultured pitui- 
tary ahenoma cells from acromegalic patients: correlation with GH 
release. Clin Endocrinol (Oxf) 30:601-611 
Lamberts SWJ, Hofland‘LJ, van Koetsveld PM, Reubi J-C, Bruin- 
ing HA, Bakker WH, Krenning EP 1990 Parallel in vivo and in 
vitro detection of functional somatostatin receptors in human en- 
docrine pancreatic tumors: consequences with regard to diagnosis, 
localization, and therapy. J Clin Endocrinol Metab 71:566-574 
Oosterom R, Verleun T, Lamberts SWJ 1983 Basal and dopamine- 
inhibited prolactin secretion by rat anterior pituitary cells: effects of 
culture conditions, Mol Cell Endocrinol29:197-212 
Oosterom R, Verleun T, Zuyderwijk J, Lamberts SWJ 1983 
Growth hormone secretion by cultured rat anterior pituitary cells, 
Effects of culture conditions and dexamethasone. Endocrinology 
113:735-746 
compared to that of octreotide, in human ovarian, breast, 
and pancreatic cancers. 
In conclusion, this study shows for the first time in primary 
cultures of human GH-secreting pituitary tumor cells and 
human gastrinoma cells that three SS analogs, available for 
clinical use, i.e. octreotide, RC-160, and BIM-23014, may 
have significant different potencies of inhibition of hormone 
release in vitro, with RC-160 being the most potent SS analog. 
It is suggested that in GH (adenoma) cells these analogs all 
act mainly via a PT-sensitive G-protein and adenylyl cyclase- 
dependent mechanism. Depending on the pharmacokinetic 
properties of these three octapeptide SS analogs, these ob- 
servations may have consequences for the medical therapy 
of patients with SS-R-positive endocrine tumors. 
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